

## Subscription and Business Information

*The American Journal of Psychiatry*, ISSN 0002-953X, is published monthly by the American Psychiatric Association.

The American Psychiatric Association does not hold itself responsible for statements made in its publications by contributors or advertisers. Unless so stated, material in *The American Journal of Psychiatry* does not reflect the endorsement, official attitude, or position of the American Psychiatric Association or of the Journal's Editorial Board.

Periodicals postage paid at Washington, DC, and additional mailing offices. POSTMASTER: Send address changes to *The American Journal of Psychiatry*, Circulation Department, American Psychiatric Association, 800 Maine Avenue, S.W., Suite 900, Washington, D.C. 20024.

### Editorial Office

*American Journal of Psychiatry*  
American Psychiatric Association  
800 Maine Avenue, S.W., Suite 900  
Washington, D.C. 20024  
E-mail: [ajp@psych.org](mailto:ajp@psych.org)

### Customer Service

Phone: (800) 368-5777 (toll-free)  
E-mail: [appi@psych.org](mailto:appi@psych.org)

### APA Member Subscription Services

Phone: (888) 35-PSYCH (toll-free)

### Subscriptions

Regular and resident-fellow members in the U.S. receive print and online access as a member benefit; subscriptions for non-members start at \$348 per year. Online only subscriptions start at \$315 per year. Go to <http://www.appi.org/products> for more information.

Institutional subscriptions are tier priced. For institutional site license or pricing information, contact (202) 559-3729 or [institutions@psych.org](mailto:institutions@psych.org).

*Additional subscription options, including single issues and student rates*

Contact Customer Service

### Advertising

*Pharmaceutical Print and Online Advertising*  
Frank Cox, Kathleen Harrison, Tim Wolfinger  
Pharmaceutical Media, Inc.  
30 East 33rd Street  
New York, NY 10016  
Phone: (212) 904-0379  
E-mail: [twolfinger@pminy.com](mailto:twolfinger@pminy.com)

*Nonpharmaceutical and Online Sales*  
Eamon Wood  
Pharmaceutical Media, Inc.  
E-mail: [ewood@pminy.com](mailto:ewood@pminy.com)  
(see address and phone above).

### Permissions and Reprints

Material published in the journals of the American Psychiatric Association and American Psychiatric Association Publishing is protected by copyright and all rights are reserved. Material may not be reproduced in any form or by any means without written permission from the copyright owner. For permission to reproduce material published by APA, please visit <http://www.appi.org/customer-service/permissions> for more information. Permission can also be secured through the Copyright Clearance Center ([www.copyright.com](http://www.copyright.com)).

APA does not require that permission be obtained for the photocopying of isolated articles for nonprofit classroom or library reserve use; all fees associated with such permission are waived. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Requests for commercial distribution and bulk reprints should be directed to (202) 609-7075.

Indexed in Abstracts for Social Workers, Academic Abstracts, Biological Abstracts, Chemical Abstracts, Chicago Psychoanalytic Literature Index, Cumulative Index to Nursing Literature, Excerpta Medica, Hospital Literature Index, Index Medicus, International Nursing Index, Nutrition Abstracts, Psychological Abstracts, Science Citation Index, Social Science Source, and Social Sciences Index.

Pages are produced by Sheridan Journal Services (Waterbury, VT) and printed by Sheridan NH (Hanover, NH) on acid-free paper effective with Volume 169, Number 1, January 2012.

© 2020 American Psychiatric Association.

PIONEERS IN

PSYCHIATRY

## Our understanding of ADHD is evolving; there is an emerging recognition that more needs to be done<sup>1-3</sup>

- More than 6 million US children and adolescents have ADHD—1 in every 10 school-aged child<sup>1</sup>

## New clinical practice guidelines have been issued for the first time in nearly a decade<sup>2,3</sup>



The American Academy of Pediatrics (AAP) released updated guidelines<sup>2</sup>

- These include screening for emotional or behavioral, developmental, and physical conditions<sup>2</sup>



The Society for Developmental & Behavioral Pediatrics (SDBP) introduced their first-ever clinical practice guideline<sup>3</sup>

- It emphasizes that clinicians with specialized expertise should initiate a **comprehensive assessment** and develop an **interprofessional, multimodal treatment plan** for any child/adolescent with **suspected or diagnosed complex ADHD**<sup>3</sup>

Get to know Supernus, scan here  
or visit [www.Supernus.com/pipeline](http://www.Supernus.com/pipeline)



**References:** 1. Centers for Disease Control and Prevention (CDC). Attention-deficit/hyperactivity disorder: data and statistics about ADHD. CDC website. <https://www.cdc.gov/ncbddd/adhd/data.html>. Accessed May 12, 2020. 2. Barbaresi WJ, Campbell L, Diekroger EA, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guidelines for the Assessment and Treatment of Children and Adolescents With Complex Attention-Deficit Disorder. *J Dev Behav Pediatr.* 2020;41(2S):S35-S57. 3. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement Management, Wolraich M, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics.* 2019;144(4):e20192528.

25-YEAR LEGACY FUELING  
THERAPEUTIC INNOVATION

 **Supernus**<sup>®</sup>  
Pharmaceuticals

Centered on CNS. Pioneers in Psychiatry.